C2N Diagnostics’ Post

Interesting MIT article on COVID and Lyme “Long covid looks exactly, and I mean exactly, like chronic Lyme.” - Michal “Mikki” Tal, MIT immunoengineer Although I wouldn't call it 'exactly', as there are many different manifestations of Lyme's Disease (also called the Great Imitator for looking 'exactly' like the majority of any chronic disease... although a better label is the Great Initiator/Facilitator/Originator, as many known chronic diseases have a subset of Lyme patients. E.g. in Alzheimer's Disease; Borrelia in the brain also causes Amyloid-beta plaque that can progress into Alzheimer's Disease, but not all Alzheimer's patients have Borrelia in their brains)... https://lnkd.in/dKqw3fGD #lyme #lymedisease #borrelia #covid #longcovid #persistentlyme

September is World #Alzheimers Month There have been significant advances in Alzheimer's research - bringing hope to this highly prevalent disease. In the last few years alone, we've witnessed the approval of the first disease-modifying treatments, learned about new pathological factors affecting disease development and will soon have access to blood-based biomarker tests. This is only the start of changing the course and impact of this devastating disease. Learn more: https://lnkd.in/gHZt7_vv $INM #Awareness #Research #AlzheimersFuture

JULY IS FRAGILE X SYNDROME AWARENESS (#FXS) MONTH! Raising awareness about Fragile X Syndrome is crucial for early diagnosis, intervention, and support. As a rare disease, Fragile X often faces challenges in research funding, leading to delays in developing effective treatments and therapies. By increasing awareness, we can drive more research and funding to better understand and manage this condition. As part of InnoSer's rare disease portfolio, we offer specialized preclinical research services using a relevant research model, allowing for efficacy testing of targeted interventions. For more information on this model and the readouts we use to assess efficacy of putative FXS treatment strategies, please refer to our website: https://lnkd.in/eqEJb7qr #FragileXSyndromeAwareness #FXSAwareness #PreclinicalNeuroscienceCRO #RareDiseaseAwareness #RareDiseaseCRO #EuropeanNeuroscienceCRO #DrugDevelopment

Join our expert faculty on September 16. Dive into the role of neuroinflammation as a therapeutic target in Alzheimer disease and highlight safety and efficacy data for investigational agents targeting neuroinflammation. Learn more: https://bit.ly/3w9PbV6 #ANA2024

🌟 Check out our top pick of the day! 🌟 📢 Stephen Fry encourages men with prostate cancer to join innovative project for better treatment of disease Read more here: https://lnkd.in/dBxbys4e 🔍 Stay informed with the best health insights and updates. Don't miss out! 🚀 #HealthNews #TopPick #medicalnews

Cogstate Chief Innovation Officer, Prof Paul Maruff, shared data at the recent ADPD meeting showcasing the association between performance on Cogstate tests and biomarkers of Alzheimer’s disease. “These relationships were strong and statistically significant,” said Maruff. “They provide for us now a basis to start to understand the absolute genesis of Alzheimer’s disease, when it begins, and how it manifests.” 📊 View the poster here: https://lnkd.in/edYxJ7hN 🎥 Watch the poster video summary here: https://lnkd.in/ePtPQXjc

🌍 Today, on #worldparkinsonsday, we raise awareness about Parkinson's disease and reaffirm our commitment to advancing research and care for those affected by this condition. Despite ongoing research efforts, the exact cause of Parkinson's disease remains elusive, highlighting the importance of collaborative initiatives like ours with Servier. Together, we aim to leverage #CausalAI and our #GeminiDigitalTwins to advance our understanding of Parkinson's Disease. Learn more about our collaboration with Servier ➡️ https://lnkd.in/epCxB6nU And read more about our work and poster presented at SfN, showcasing evidence from our Gemini Digital Twins that suggests that Alzheimer's disease and Parkinson's disease might share common genes and pathways that causally influence a neuro-common biomarker, along with disease-specific clinical progression rates ➡️ https://lnkd.in/eUtwbZYW #ShareYourSpark ⚡ #Aitia #ATeam #ParkinsonsDisease #ParkinsonsAwareness #CNS

Today is a #RareDiseasesDay – here a brief reflection on diseases that affect so few, yet impact so many.   Rare diseases are not just a medical challenge, but a profound test of our collective commitment and innovation. It is an area that is often overshadowed by healthcare, as the conditions affect less than 1 in 2,000 people, yet it is worth remembering that collectively, rare diseases affect more people than cancer and Alzheimer's disease combined. Unlike more common diseases, where many guidelines exist and treatments are rapidly evolving, rare diseases - despite the huge medical advances that have been made in recent years - remain in the realm of ambiguity, with fragmented care pathways and limited treatment options.   At J&J, we understand very well the challenges that these patients face - from the diagnostic odyssey of many years to the diagnosis full of uncertainty, to the uncertainty related to the possibility or availability of optimal treatment. That is why we joined this remarkable journey in rare disease research many years ago. These have resulted in, among other things, pioneering treatments for rare diseases such as mantle cell lymphoma (MCL) and light chain amyloidosis (AL.), as well as involvement in the treatment of inherited retinal diseases (IRDs), which we are trying to redefine.   At J&J, I am proud to say that our commitment to patient-centered innovation is not just a lofty ideal; it is deeply rooted in our Credo, ensuring that the voices of patients echo in every decision we make, driving us towards the most unmet needs in the area of rare diseases, which we can address by combining our innovative actions and years of experience.   Together, let's continue to shine a light on rare diseases, leaving no patient behind on their journey towards hope and healing.   #rarediseaseawarness #patientfirst #healthcare #innovation

A lab test for #AlzheimersDisease with diagnostic accuracy as reported in this #JAMA paper is a HUGE advancement, and is key to enabling primary care physicians with a tool to identify the disease earlier, an important step in early identification of the disease... Paired with the #LancetCommissions findings this year on how to modify risks with lifestyle interventions, new therapeutic options, we really have tools to fight #dementia as well as to advance #precisionmedicine similar to in oncology.... https://lnkd.in/eutGybes

Alzinova AB has reached another important milestone! We are happy to share that Alzinova has achieved a significant milestone in our fight against Alzheimer's disease. All patients in the extension part (part B) of our phase 1b study, with the vaccine candidate ALZ-101, have now received their last dose. This marks an important step forward in our mission to develop innovative treatments for Alzheimer's disease. With strong safety and tolerability data from part A and positive antibody response results, part B will provide valuable insights into the long-term effects of ALZ-101. As we move closer to our phase 2 study, we are hopeful that ALZ-101 could pave the way for more effective therapies against this terrible disease. Stay tuned for more updates on our progress! #AlzheimersResearch #ALZ101 #MedicalInnovation